All-Cause Healthcare Resource Use in Recurrent Respiratory Papillomatosis: A Claims-Based Comparison With Matched Controls
Author(s)
Megan Bourque, PhD1, Allison Perry, PhD2, Becky Hollenberg, MPH2, Samantha Rothstein, BSc2, Barkha P. Patel, PhD1, Mostafa Shokoohi, PhD1, Daniel Park, PhD2, Rahul Das, PhD2, Joe Merkert, BA3.
1CRG-EVERSANA, Burlington, ON, Canada, 2Norstella, Yardley, PA, USA, 3Precigen, Germantown, MD, USA.
1CRG-EVERSANA, Burlington, ON, Canada, 2Norstella, Yardley, PA, USA, 3Precigen, Germantown, MD, USA.
OBJECTIVES: Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease caused by infection with human papillomavirus (HPV) type 6 or 11 with limited real-world data on its economic and healthcare impact. This study compared all-cause healthcare resource utilization (HCRU) between RRP patients and matched controls in the United States (US).
METHODS: Adults with confirmed RRP were identified using NorstellaLinQ’s electronic medical records, linked to NorstellaLinQ’s closed claims, with ≥6-months continuous enrollment pre- and post-randomly assigned anchoring index date (1/1/2023) to capture patients with varying history and severity. Patients with RRP were propensity-score matched to non-RRP controls on age, sex, region, and payer. All-cause HCRU was compared between groups.
RESULTS: The matched cohort included 166 RRP patients and 498 controls with similar demographics (mean age: 48.9 vs. 49.5 years; % male: 59.0% vs. 58.4%). Patients with RRP had significantly more emergency (rate ratio [RR] 2.28; 95% confidence interval [CI]: 1.50-3.43), inpatient (RR=12.23; 95% CI: 7.90-19.58), and outpatient visits (RR=2.92; 95% CI: 2.07-4.10) pre-index; inpatient and outpatient visits remained significantly higher post-index. Medication use was significantly higher in RRP patients in both periods: opioids (pre-index: RR=7.47; 95% CI: 6.24-8.96); non-opioids (pre-index: RR=2.09; 95% CI: 1.67-2.61); and mental health medications (pre-index: RR=3.50; 95% CI: 2.99-4.08). Speech therapy (RR=70.50; 95% CI: 18.46-599.19), mental health visits (RR=4.31; 95% CI: 3.53-5.27), chest imaging (RR=6.31; 95% CI: 4.93-8.12), and anesthesia (RR=5.88; 95% CI: 3.52-10.05) were significantly higher in RRP patients pre-index, with similar trends post-index. No controls underwent tracheotomy; one RRP patient had one tracheotomy in each period.
CONCLUSIONS: Although rare, RRP is associated with substantial HCRU in the US. Higher emergency/healthcare visits, opioid use, and mental health service needs highlight the significant burden of RRP on patients’ quality of life.
METHODS: Adults with confirmed RRP were identified using NorstellaLinQ’s electronic medical records, linked to NorstellaLinQ’s closed claims, with ≥6-months continuous enrollment pre- and post-randomly assigned anchoring index date (1/1/2023) to capture patients with varying history and severity. Patients with RRP were propensity-score matched to non-RRP controls on age, sex, region, and payer. All-cause HCRU was compared between groups.
RESULTS: The matched cohort included 166 RRP patients and 498 controls with similar demographics (mean age: 48.9 vs. 49.5 years; % male: 59.0% vs. 58.4%). Patients with RRP had significantly more emergency (rate ratio [RR] 2.28; 95% confidence interval [CI]: 1.50-3.43), inpatient (RR=12.23; 95% CI: 7.90-19.58), and outpatient visits (RR=2.92; 95% CI: 2.07-4.10) pre-index; inpatient and outpatient visits remained significantly higher post-index. Medication use was significantly higher in RRP patients in both periods: opioids (pre-index: RR=7.47; 95% CI: 6.24-8.96); non-opioids (pre-index: RR=2.09; 95% CI: 1.67-2.61); and mental health medications (pre-index: RR=3.50; 95% CI: 2.99-4.08). Speech therapy (RR=70.50; 95% CI: 18.46-599.19), mental health visits (RR=4.31; 95% CI: 3.53-5.27), chest imaging (RR=6.31; 95% CI: 4.93-8.12), and anesthesia (RR=5.88; 95% CI: 3.52-10.05) were significantly higher in RRP patients pre-index, with similar trends post-index. No controls underwent tracheotomy; one RRP patient had one tracheotomy in each period.
CONCLUSIONS: Although rare, RRP is associated with substantial HCRU in the US. Higher emergency/healthcare visits, opioid use, and mental health service needs highlight the significant burden of RRP on patients’ quality of life.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE44
Topic
Economic Evaluation, Study Approaches
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Rare & Orphan Diseases, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)